Richard Klausner
CIK 1591178 · Executive Chairman · last filed 2026-06-11
Richard Klausner is an Executive Chairman who has filed 47 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for PBLS, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$11.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $55.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$55.13M
4
47
-$11.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBLS | Director | — | — | — | $0 | 1 | 2026-06-11 |
| LYEL | Director | 3,811,199 | $13.50 | $51.45M | -$108.4K | 9 | 2025-05-19 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 0 | — | — | -$10.49M | 27 | 2018-03-07 |
| ILMN | Sr VP, Chief Medical Officer | 22,847 | $160.97 | $3.68M | -$420.0K | 10 | 2016-02-01 |
Recent Filings
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | PBLS | Grant (A) | — | $0 | EDGAR |
| 2025-05-19 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | LYEL | Buy (P) | +158,000 | $94.9K | EDGAR |
| 2024-06-17 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-09-08 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-08-17 | LYEL | Sell (S) | −58,020 | -$132.3K | EDGAR |
| 2023-06-20 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2022-09-27 | LYEL | Sell (S) | −11,100 | -$71.0K | EDGAR |
| 2022-06-10 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2021-06-23 | LYEL | Conv (C) | +3,765,842 | $0 | EDGAR |